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Recent upsurge in the interest of breast cancer metastasis is partly attributed to the discovery of novel, yet unclear, mechanisms of
breast cancer interaction with sites of distant metastasis such as the bone marrow microenvironment. In this review, we discuss the
signiﬁcanceoftheinteractionsbetweenbreastcancercellsandcellsofthebonemarrow.Thisisasubjectofintenseresearchstudies
aim to provide new methods of treatments and perhaps the identiﬁcation of new drug targets. This review also discusses the role
of inﬂammation and the bimodal function of the transforming growth factor-β signaling pathway in the process of tumorigenesis.
We bring attention to future prospects in breast cancer research, including the role of microRNAs in cancer quiescence in the
bone marrow and the application of microRNAs to basic science discoveries in oncology. Finally, we discuss the cancer stem cell
hypothesis, which is not a new idea, but has resurged with investigative questions.
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1.Introduction
Breast cancer, despite the subject of intense investigations,
remains the most common cancer among women in the
United States and the second leading cause of cancer death
among this group. Each year, over 44000 females die from
breast cancer [1]. The current long-term prognosis for breast
cancer is not favorable, and there remains a great deal
of room for improvement in treatments, which could be
derived from research [2]. Eﬀorts to detect breast cancer
early,althoughsuccessful,donotguaranteesurvival[3].This
indicates that either more sensitive methods are needed to
detect breast cancer, or it is important to understand the very
early events of breast cancer biology.
The brain, bone, liver, and lungs are preferred sites of
metastasis. Metastases have been reported to occur even
in the absence of a primary tumor, signifying the perilous
nature of this process, a subject that is revisited later in
this review [4]. Metastasis to bone results in both physical
and physiological imbalances such as lytic lesions and
hypercalcemia [5].Fractures,compressionofthespinalcord,
and reduced quality of life are the ultimate outcomes of
bone metastasis [5]. Recent improvements in chemother-
apy for advanced breast cancer treatment, although to be
credited, have shown limited success, as chemotherapy fails
to target quiescent breast cancer cells in the bone marrow
[2].
The phenomenon of breast cancer cell quiescence in
the marrow cavity has received attention, and several
mechanisms of dormancy, as well as tertiary metastasis
from the bone marrow, have been proposed [6]. Patho-
logical triggers such as infection can promote release of
both lymphocytes and cancer cells from the bone marrow.
This suggests that infection can lead to tertiary metastasis
of breast cancer. Although research studies have been
conducted to understand the complex interplay between
breast cancer cells and the bone marrow microenviron-
ment, the mechanism remains unclear, but the signif-
icance of this disease process merits in-depth research
studies.2 Journal of Oncology
2.The Cancer Cell/Bone MarrowInterface:
Molecular Interactions
Molecular mechanisms of bone marrow interactions with
breast cancer cells have been addressed [3] .T h er o l eo f
stromal cell-derived factor 1α (SDF-1α)h a sb e e ng i v e n
considerable attention. Bone marrow stromal cell expression
of SDF-1α is a key consideration to understand breast cancer
cell entry and integration into the bone marrow. In the
region of the endosteum, SDF-1α expression from stromal
cells interacts with the chemokine receptor 4 (CXCR4) [3].
SDF-1α-CXCR4 interactions have also been linked to the
interface between the periphery and bone marrow cavity,
thereby bringing this chemokine-receptor pair as relevant
to the entry of breast cancer cells into bone marrow.
Knockdown of SDF-1α in breast cancer cells resulted in
reduced eﬃciency to cancer cell entry into bone marrow [3].
Following exogenous supplementation of SDF-1α,c o n t a c t
between these cells was rescued, emphasizing the critical
role of SDF-1α in the breast cancer cell/bone marrow
microenvironment [3].
Since both breast cancer cells and hematopoietic stem
cells express the CXCR4 receptor, it is possible that both
the endogenous hematopoietic stem cells and the cancer
cells can compete for “docking” to the stroma cells. During
quiescence, the breast cancer cells themselves protect bone
marrow destruction by decreasing the expression of SDF-1α,
which would allow the hematopoietic stem cells to interact
with stromal cells rather than the cancer cells, explained in
Figure 1 [3].
We now turn out attention to the neurokinin 1 (NK1)
receptor because it has been closely implicated in breast
cancer interaction in the bone marrow. The interaction
between SDF-1α and CXCR4 is regulated by the NK1
receptor, a seven-transmembrane G-protein-coupled recep-
tor (GPCR) that has been implicated in hematological and
solid malignancies [7]. The NK2 receptor has a somewhat
diﬀerent function and suppresses hematopoiesis [8]. The
NK1 and NK2 receptors demonstrate reciprocal regulation
and have opposing functions in normal cells [9].
The NK1 receptor is constitutively expressed in neural
tissue but inducibly expressed in bone marrow cells and
breast epithelial cells [10, 11]. The NK1 receptor interacts
withpeptidesbelongingtomembersofthetachykininfamily.
The tachykinins are encoded by the preprotachykinin-1
(Tac1) gene of which the major product is the undecapeptide
substance P [12]. The Tac1 gene also produces the decapep-
tide neurokinin A, neuropeptide K, and neuropeptide-γ.
These products function in cell secretion and vasodilation
[10]. Interactions between peptides of Tac1 and NK1 are
involved in hematopoietic regulation, depending on the
interacting peptide or the signaling receptor [10]. In nontu-
morigenic MCF12A breast cells, activated nuclear factor-κB
(NF-κB) has been shown to suppress Tac1 expression level in
the presence of high levels of SDF-1α [12]. Thus, the NK1
receptor oﬀers a valuable pharmacologic target in diseases





Figure 1: Model of bone marrow and cell migration patterns by
breast cancer cells. Breast cancer cells entering the bone marrow
with mesenchymal stem cells aiding the entry of the cancer cells
are shown.The ﬁgure also shows the migrations of cancer cells to




cell metastasis to the marrow cavity have implicated a central
role for Tac1.T h i sg e n ea p p e a r st oh a v ea ni n t e g r a lr o l ei n
the molecular interaction between breast cancer cells and
mesenchymal stem cells, which the cancer cells encounter
upon entering the bone marrow cavity [12]. Tac1 appears
to regulate this interaction by regulating the expressions
of SDF-1α and CXCR4 on both the cancer cells and
mesenchymalstemcells.Theserecentﬁndingsareinteresting
as they could lead to future studies to deﬁne a new method
of treatment by targeting the SDF-1α-CXCR4 interactions,
and also to target the Tac1 gene. Such treatments could
be possible in the near future due to the availability of
CXCR4 antagonists [12]. In summary, we propose that Tac1
contributes to breast cancer cell metastasis and integration
into bone marrow stromal compartment [9]. Additionally,
Tac1 manages the transition of breast cancer cells into a
quiescent phenotype in the marrow cavity.
Recent studies suggest that particular breast cancer cell
subset shows preference for the bone marrow and this
preferredsitecouldbeatanearlystageofthedisease,perhaps
prior to clinical detection [6]. At this early phase, if the cells
undergo quiescence, they are supported by the bone marrow
microenvironment and are likely to resist chemotherapy. It
would be diﬃcult to ignore the presence of mesenchymal
stem cells at the abluminal region of blood vessels in bone
marrow since they could identify avenues of treatment [6].
In addition to being able to facilitate coupling with cancer
cells, mesenchymal stem cells also exert immune suppression
so that the cancer cells can evade immune clearance. Thus, it
isunderstandablewhythecancercellsinbonemarrowwould
have advantages to evade detection and protection from the
innate immune system [6]. The next section selects TGF-β to
discuss how this cytokine facilitates breast cancer cells to be
established in bone marrow.Journal of Oncology 3
3. GenesLinkedto VariousStages of
Breast Cancer in Bone Marrow:
Relevance toResident Stem Cells
The spectrum of eﬀects of TGF-β in breast cancer biology is
vast, yet somewhat ambiguous. In the early stages of breast
cancer growth, TGF-β functions as a tumor suppressor due
to its antiproliferative eﬀects [13, 14]. In later stages, TGF-
β promotes cancer cell proliferation and metastasis, thereby
functioning as an oncogene [13]. This bimodal function
has been attributed to changes in the responsiveness of
cancer cells to TGF-β. Thus, during the early stage of breast
cancer development, the cells are sensitive to TGF-β,wh e r e a s
the malignant cancer cells, as well as other carcinomas,
lose this sensitivity [13]. With regards to mechanism, the
TGF-β/SMAD signaling pathway has been attributed to the
inhibition of breast cancer cell proliferation [13]. TGF-β also
alters the microenvironment and immune responses that
may provide favorable conditions for cancer maintenance
[15].
The promotion of apoptosis by TGF-β has been linked to
its interactions with the Survivin gene, which is a member
of the inhibitor of apoptosis (IAP) family. TGF-β can
downregulate the expression of Survivin at the level of gene
transcription, resulting in apoptosis [14]. Evidence suggests
that TGF-β downregulates Survivin via activin-like kinase 5
(ALK5)inanSMAD2-andSMAD3-dependentmanner[14].
Experimental studies suggest that altered levels of Sur-
vivincausechangesinthereceptivenessofcellstoTGF-β,and
also other cytokines responsible for inducing apoptosis [14].
These ﬁndings could be signiﬁcant for combating cancer,
sinceregulatingSurvivin levelscouldmakebreastcancercells
more susceptible to the apoptotic-inducing aﬀect of TGF-β.
TGF-β has the ability to arrest the cell cycle progression
in G1 phase via the pRb tumor suppression mechanism,
thereby preventing the S phase entry and breast cancer cell
proliferation [16]. However, under the regulation of c-myc,
breast cancer cells become less susceptible to the eﬀects of
TGF-β [16]. Point mutations have been identiﬁed in the
TGF-β receptor 1 (TGFR1) in breast cancer cells [13]. In
contrast, mutation in the SMAD family is rarely associated
with breast cancer [13]. Whereas limited expression of
the type 2 TGF-β receptor in other cancers has been
accredited to point mutation, in breast cancer it is due to the
unresponsivenesstotheligandTGF-β[13].Boththereceptor
and its intracellular signaling components are critical for
regulating cell proliferation. In addition to these properties,
TGF-β f o r m sn e t w o r k sw i t ho n c o g e n e ss u c ha sc-myc to
modulate expression of other genes linked to tumorigenesis
such as Tac1 [13]. TGF-β exerts its inductive eﬀects on Tac1
via c-myc [16]. An interesting study demonstrated that TGF-
β levels were signiﬁcantly decreased in cocultures of breast
cancer and bone marrow, unlike insulin-like growth factor
[16]. Taken together, these extensive ﬁndings indicate that
the TGF-β signaling pathway provides a valuable target for
anticancer eﬀorts.
Recent reports uncovered homology between the seven-
transmembrane receptor, NK1, and the hematopoietic
growth factor inducible neurokinin-1 type (HGFIN), also
referred to as nmb [7, 17]. This ﬁnding is relevant because
both NK1 and HGFIN have been linked to tumorige-
nesis, including breast cancer [7]. HGFIN is a type I
transmembrane glycoprotein that maps to the short arm
of chromosome 7 and shares structural homology to the
NK1 receptor and murine Osteoactivin [7]. Based on the
homology between HGFIN and the NK1 receptor, it would
belogicalforonetopresumecommonfunctionsbythesetwo
membrane proteins in cancer biology. However, their roles
are contrasting. While NK1, in its truncated form, exerts
oncogenic properties, HGFIN shows tumor suppressor roles
[7].
HGFIN can interact with the major Tac1 peptide, sub-
stance P [17]. HGFIN and its murine analog, Osteoactivin,
exert various functions [17] .T h ee v i d e n c es u p p o r t sat u m o r
suppressive role of HGFIN. Its expression has been reported
in lowly aggressive melanoma as compared to the highly
aggressive melanoma [17]. The suggestion is that the role
of HGFIN in melanoma may be attributed to its homology
with the melanocyte-speciﬁc protein pMEL17 [17]. In breast
cancer cells, HGFIN suppresses their growth and migration
[17].
Similar to most tumor suppressors, HGFIN has also
been linked to the potentiation of tumor formation but
suppresses cell invasiveness. Overexpression of its homolog,
Osteoactivin, has been associated with increased metastatic
ability and osteolytic lesion formation in 4T1 murine breast
carcinoma [5]. The transcription factor, p53, binds to
multiple sites in the 5  ﬂanking region of HGFIN [16]. The
limited role of HGFIN/Osteoactivin warrants future research
into its link to cancer. Information on this gene has just
begun as its involvement in cancer biology could be linked
to the NK receptor gene family as well as the Tac1 gene. The
genes highlighted in this section have been associated with
the biology of hematopoietic and mesenchymal stem cells
[6]. Thus, these genes need to be addressed when the biology
of breast cancer is studied in bone marrow with the inclusion
of the two major bone marrow resident stem cells.
4. microRNAs: Breast Cancer Link
Recent research in the ﬁeld of oncology, especially breast
cancer,hasfocusedontheconceptofmicroRNAs(miRNAs).
The technology of miRNA analyses has been employed
to study the regulation of gene expression. These novel
nucleotides have been implicated in cancer, myogenesis, dif-
ferentiation of neurons, and stem cell renewal [18]. miRNAs
are noncoding RNA molecules that are extensively processed
before exerting their eﬀects on endogenous transcripts [19].
A pri-miRNA is transcribed and then processed by Drosha
and Pasha, resulting in the formation of a pre-miRNA [20].
Upon nuclear export of the pre-miRNA, it is processed in
the cytosol, forming an miRNA-induced silencing complex
(RISC), in which the miRNA binds to the 3  untranslated
region (UTR) of endogenous messenger RNAs [20]. Thus,
miRNAs exert their eﬀect at the translational level and
are valuable in regulating gene expression. Unlike RNA
interference, the RISC that is associated with miRNAs does4 Journal of Oncology
not lead to degradation of the complex but instead leads to
inhibition of endogenous message expression [20]. To date
there are >500 miRNAs in the human genome [20]. The
Tac1 gene, which is linked to breast and other cancers [18],
could be suppressed by translational inhibition [18]. Tac1,
described above, regulates breast cancer cell interaction with
themesenchymalstemcells[12].Thus,miRNAsagainstTac1
may aﬀect quiescence of breast cancer cells in the marrow
cavity [12]. Three miRNAs have been found that may bind
to Tac1: miR-130a, miR-206, and miR-302a [17].
In addition to breast cancer, miRNAs have been impli-
cated in the disease processes of lung cancer, colorectal
cancer,anddiﬀuselargeBcelllymphoma[19].Anexpression
proﬁle of miRNAs has been identiﬁed for pancreatic ade-
nocarcinoma, including miR-221, miR-376a, miR-301 [19].
Dysregulation of miR-124 and miR-137 occurs in glioblas-
tomas [20]. These ﬁndings represent only a fraction of our
currentknowledgeofmiRNAinvolvementinmalignancy,yet
much remains to be discovered.
Inadditiontotheirroleinmalignancies,miRNAsarealso
involved in stromal cell interaction with hematopoietic stem
cells (HSCs) and the neural-hematopoietic-immunological
system. Production of hematopoietic regulators including
cytokines, neuropeptides, and neurotransmitters is involved
in HSC functioning. Additionally, stromal cells are adaptive
in their ability to respond to the aforementioned regulators
[8]. Furthermore, miRNAs have been proposed to serve
as the link between cancer and chronic inﬂammation (see
Inﬂammation and Carcinogenesis), although the precise role
of miRNAs in these biological processes is unclear.
5. Inﬂammation and Carcinogenesis
The bridge between carcinogenesis and chronic inﬂamma-
tion has been under investigation. It has been suggested
that chronic inﬂammation can promote the formation of
cancer due to increased resistance to apoptosis and increased
proliferation of the aﬀected cells [21]. Furthermore, reactive
oxygen and nitrogen species which are induced by the
inﬂammation process damage vital components of the target
cell such as DNA, lipids, and protein [21]. Such damage has
often contributed both directly and indirectly to malignant
cell transformation. Also, the abnormal or overexpression of
cytokines and other proinﬂammatory regulators, as well as
molecules integral in intermolecular communication, pro-
motes tumor proliferation [21]. Many cytokines commence
the angiogenesis process and therefore the cancer-stromal
cell communication [21].
Tumor necrosis factor α (TNF-α), a proinﬂammatory
cytokine, has multiple roles in the development of cancer.
Whereas it is potentially destructive to tumor vasculature
when expressed in high concentrations, it can also facilitate
tumor cell growth, including growth of breast cancer cells
[21]. Mice deﬁcient in TNF-α or its receptor show resistance
to carcinogenesis, suggesting the oncogenic potential of
TNF-α [21].
Interleukin-6 (IL-6) is also a proinﬂammatory cytokine
and an acute phase reactant [22]. Speciﬁcally, IL-6 regulates











Figure 2: Granzyme B in cancer targeting. Granzyme B expression
isincreasedasCTLsmature.WhileCD44ismoderatelyexpressedin
the early stages of CTL maturation, its expression increases during
the maturation process. A mechanism by which antigen priming
with IL-2 and IL-15 increases granzyme B induction is shown. In
contrast, IL-21 is shown to cause opposing eﬀect [22].
progression [22]. Elevated IL-6 levels have been liked to the
pathogenesis of cancer [22]. Treatment with anti-IL-6 results
in reduced expression of the antiapoptotic protein Mcl-1,
suggesting that IL-6 controls Akt-dependent survival signals
[22].
T h er o l eo fI L - 2i nc a n c e rc e l la n e r g yh a sb e e nd e m o n -
strated. IL-2 has been shown to stimulate activation-induced
cell death (AICD) as well as the proliferation of regulatory T
(Treg) cells [23]. Treg cells harbor a CD4+/CD25+ phenotype
and are classiﬁed into at least two types: Foxp3+ Treg
cells utilize granzyme A to induce cell apoptosis, and
Tr1/Th3 Treg cells utilize granzyme B [24]. Treg cells can
suppresseﬀectorTcellfunctionandautoimmunity[25].The
mechanisms of Treg-mediated immune suppression involve
contact-dependent delivery of inhibitory signals resulting in
cancer cell anergy [26].
In addition to its eﬀects on Treg cells, IL-2 has also been
shown to promote the maturation of cytotoxic T lympho-
cytes (CTLs) to mature cells expressing CD44 and granzyme
B[23].Amorecompletecomprehensionoftheconsequences
of these signals on CTLs is integral in the pursuit of a
more eﬀective method of adoptive immunotherapy. When
activated by IL-2, CTLs have the capability to lysetumor cells
[23]. Forthis reason, IL-2hasbeen usedto generateTcellsto
treat cancer by cell transfer techniques [23]. Additionally, IL-
2 promotes CTL activation and proliferation [23]. In clinical
cases, administration of IL-2 has led to cancer regression
[23].
On the other end of the interleukin spectrum, IL-21 neg-
atively regulates the eﬀects of IL-2 (Figure 2). This demon-
strates the antagonistic relationship that exists between the
aﬀects of IL-2 and IL-21 on CTLs with respect to cancer.
IL-21-primed T cells were found to have the strongest
antitumor response, but only in a small percentage of trials.
Thus, the antitumor potential of IL-21 could be promising
in future applications. Such ﬁndings are vital to adoptive
immunotherapy and its implications in cancer. The potential
forimmune-relatedtherapyinthetreatmentofcancermerits
further investigation into the interplay between IL-2 and IL-
21 [23].
In addition to the anticancer potential of IL-21, another
member of the type I cytokine family, IL-15, has also beenJournal of Oncology 5
shown to have antiproliferative eﬀects. IL-2 and IL-15 both
promote antigen-speciﬁc cytolytic activity [23]. Despite the
vast number of reports on T-cell signaling, the network and
intracellular pathways triggered by T cell activation need
further investigations.
The link between inﬂammation and stem cell in breast
cancer biology is most evident in the recent studies demon-
strating the anti-inﬂammatory eﬀects of mesenchymal stem
cells [27,28].Althoughmesenchymalstemcelltherapyisnot
currently a target for cancer, further basic science research
into their role in inﬂammation and cancer may provide
insight into molecular processes governing the link between
cancer and inﬂammation.
6. Cancer Stem Cells: New Discoveries on
aT rad itio nalI d ea
The classical model for cancer is based on stochastic events
that occur in a cell [1]. This model holds that a series
of mutations can lead to cell transformation [1]. The
development of chemotherapy agents has largely been based
on this model. Recently, the concept of the cancer stem
cells (CSCs) has received much attention, yet the pioneering
work on the concept of the CSCs was made as early as
1 5 0y e a r sa g o .D r .J a m e sT i l lh e l p e dd e ﬁ n et h et e r mstem
cell and, together with Dr. Ernest McCullough, coined the
term cancer stem cell on the basis that cancer might arise
from stem cells. The CSCs hypothesis is based on the
identiﬁcation of a unique population of stem cells in the
bone marrow [29]. Among other reasons, the observation
of a heterogeneous population of cells in tumors such as
glioblastoma multiforme accounts for continued interest in
the theory [30].
CSCs are tumorigenic multipotential cells with dys-
regulated self-renewal properties [31]. Upon division, one
daughter cell retains stemness and the other becomes
committed to a lineage [31]. The CSC fraction typically
constitutes 1–5% of the tumor size [32]. They function in
initiation, maintenance, growth, and metastasis of tumors
[33, 34]. CSCs, like other stem cells, provide continuous
source of cancer cells with limited life span, analogous
to cancer progenitors. The hypothesis holds that tumors
arise from developmentally arrested stem cells harboring
mutations, and such characteristics promote tissue repair
and organogenesis [30]. They demonstrate slow cycling
and indeﬁnite ability to renew themselves [30]. They can
proliferate limitlessly and are more resistant to chemother-
apy and apoptosis than somatic cancer cells [35]. The
resistanceofCSCstochemotherapyandradiationisthebasis
for heightened interest in research endeavors in the CSCs
hypothesis [30].
Evidence is gradually accumulating on the CSCs hypoth-
esis,asnumerousmalignancieswithstem-cell-likeproperties
have been identiﬁed. A fraction of rat glioma cells have been
found to be CD133+ cells with stem cell characteristics [36].
Gliomas contain 10-fold greater levels of CD133+ cells than
normal tissue, suggesting properties of stemness in tumors
[37]. CSCs have also been identiﬁed for medulloblastomas
and oligodendrogliomas [29] .Ar e c e n tr e p o r td e m o n s t r a t e d
that only CD133+ medulloblastomas and gliomas can
generate tumors, with as few as 100 cells being able to
recapitulate a tumor [35]. Squamous cell carcinoma of the
oral cavity has been shown to be positive for the stem cell
markers Oct-4, Nanog, Nestin, CD117, and CD133 [33].
These aforementioned ﬁndings are just a few pieces of
evidence supporting the CSC hypothesis.
The putative breast carcinoma stem cell has received
much attention. Normal stem cells of the breast can give
rise to ductal epithelia, alveolar epithelia, and myoepithelia
[1]. The multilineage diﬀerentiation and self-renewal prop-
erties of stem cells are evident in cells expressing CD24
and integrins β1a n dα6. The breast CSCs phenotype is
CD44+/CD24−/lin-, and as few as 200 cells of this phenotype
can generate a tumor in NOD/SCID mice [1]. The same
study demonstrated that 20000 breast cells without this
phenotype were unable to recapitulate a tumor, suggesting
the signiﬁcance of cancer cells with stem-like properties [1].
HER2 overexpression has been associated with increased
expression of the stem cell marker aldehyde dehydrogenase
(ALDH) [32]. Furthermore, fractions of stem cell progen-
itors in breast tumors increase in the presence of HER2
overexpression [32]. ALDH has been suggested as a stem cell
marker that may give insight into characterization of CSCs
[38].
Current chemotherapeutic treatment for cancer typically
reduces tumor burden without eliminating all the cancer
cells. To date, the classical cancer model has been the
foundation for advances in cancer treatment. However, the
high level of resistance of tumors to chemotherapy lends
much support to the CSC model [1]. Multiple characteristics
of CSCs account for resistance to chemotherapy and radi-
ation, including lack of a targetable phenotype and speciﬁc
oncoprotein expression, high level of MDR1 expression, and
slow cycling rate [32]. Cell-based therapy involving T cells
has been proposed for the targeting of CSCs. T cells have
been shown to eliminate tumors by directly targeting tumor-
associated antigens [39]. For practical purposes, however, a
T-cell-based regimen is diﬃcult to administer and fails to ﬁt
into the conventional pharmacology model [39].
The signiﬁcance of the CSC theory is evident from many
perspectives, such as survival analyses. Triple-positivity for
Oct-4, Nanog, and CD133 in oral squamous cell carcinoma
rendersthepoorestprognosis ofallsquamouscellcarcinoma
patients [33]. These ﬁndings indicate the lethality of the
CSC and merit attention to CSCs as a future target for
cancer chemotherapy. By eliminating the centrally located
multipotential cell characterized by dysregulation of self-
renewal ability, the source of maintenance and growth of
tumors would be terminated.
Fromapharmacologicstandpoint,methodsarecurrently
being devised to suppress CSCs. For instance, an alkylating
agent used in chemotherapy for glioblastoma multiforme
fails to aﬀect CSCs that are inherently resistant [40]. The
use of chloride channel antagonists, however, has shown to
induce apoptosis of these CSCs [41]. The use of monoclonal
antibodies to target CSCs has been proposed based on the
ideas that antibodies can interfere with cancer cell signaling6 Journal of Oncology
pathways, assist in the delivery of anticancer agents, and
facilitate an immune response to tumors [34]. This approach
is beneﬁcial because it attempts to speciﬁcally target CSCs
and to eﬃciently destroy the tumor while exerting minimal
damage to healthy cells. Monoclonal antibody therapy for
CSCs may thus improve prognoses [34]. Clearly, much room
for pharmacological therapy against CSCs exists.
7. Outlook: Courses of Action to
Combat Breast Cancer
The link between the chronic inﬂammation process and
cancer growth will continue to be investigated in order
to fully understand the possible functions of the various
interleukins as they would relate to preventing cancer cell
proliferation. Future prospects include harnessing IL-2-
induced maturation of CTLs to induce apoptosis in cancer
cells.Also,thereisapossibilityofusingIL-21-primedmature
CTLs as a form of external treatment as it has been shown
thattheyhavestrongantitumorproperties.TGF-β couldalso
be a signiﬁcant player in future treatments of breast cancer.
Harnessing its capability to arrest the cell cycle progression
would be a monumental step in the combating cancer.
Theanti-inﬂammatorypropertiesofmesenchymalstemcells
may be of value in the future of breast cancer therapy, as sites
ofinﬂammationfacilitatecancerbypreventingapoptosisand
promoting cellular proliferation [21]. Clearly, prospects for
the future in oncology research are vast.
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